---
title: "ZYPEEK: Wang Xiuyun plans to reduce holdings by no more than 1% of shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252004510.md"
description: "According to the Zhitong Finance APP, ZYPEEK announced that Wang Xiuyun intends to reduce holdings of no more than 1.2168 million shares through centralized bidding, not exceeding 1% of the company's total share capital. Among them, the total number of shares reduced within any consecutive 90 natural days shall not exceed 1% of the total number of company shares, and the reduction period will take place within three months after the fifteenth trading day from the date of announcement"
datetime: "2025-08-07T10:09:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252004510.md)
  - [en](https://longbridge.com/en/news/252004510.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252004510.md)
---

# ZYPEEK: Wang Xiuyun plans to reduce holdings by no more than 1% of shares

According to the announcement from ZYPEEK (688716.SH), Wang Xiuyun plans to reduce her holdings by no more than 1.2168 million shares through centralized bidding, which does not exceed 1% of the company's total share capital. The total number of shares to be reduced within any consecutive 90 calendar days shall not exceed 1% of the total number of company shares, and the reduction period will take place within three months after the fifteenth trading day from the date of the announcement

### Related Stocks

- [688716.CN](https://longbridge.com/en/quote/688716.CN.md)

## Related News & Research

- [Best of BS Opinion: FTA strains, virus alerts, and market reform debate](https://longbridge.com/en/news/286835751.md)
- [Europe-China spacecraft launches to study Earth's 'invisible armour'](https://longbridge.com/en/news/286881963.md)
- [Marvel Biosciences Announces Grant of Deferred Share Units | MBCOF Stock News](https://longbridge.com/en/news/287056256.md)
- [Apple Flavor to Buy NovoSana’s China Assets for Up to USD66 Million in Health Supplements Push](https://longbridge.com/en/news/287039106.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)